Amblyopia Clinical Trial
Official title:
Evaluation of the GoCheck Kids Mobile Vision Screening Application and the Welch Allyn Spot Vision Screener
Verified date | February 2023 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators are conducting a prospective evaluation of the ability of two vision photoscreening devices (GoCheck Kids and the Welch Allyn Spot Vision Screener) to detect risk factors for amblyopia. Photoscreeners function similar to having a picture taken with a camera. Amblyopia is decreased vision in one or both eyes due to decreased vision development in the brain resulting from decreased visual stimulation. Children ages 1 year to less than 7 years of age referred to a pediatric ophthalmologist at Yale New Haven Health and Yale Medicine locations for a failed vision screen will be offered participation. The ability of each screening device to detect amblyopia risk factors will be compared with the results of a complete eye exam performed by the practitioner.
Status | Completed |
Enrollment | 227 |
Est. completion date | December 19, 2022 |
Est. primary completion date | December 19, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 7 Years |
Eligibility | Inclusion Criteria: - Children ages 1-<7 years. Exclusion Criteria: - Children with a history of ocular surgery and children with ocular conditions or behavior that preclude obtainment of the screening photo images or completion of a complete eye exam. - Children with an obstructed visual axis. |
Country | Name | City | State |
---|---|---|---|
United States | Yale New Haven Hospital | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Vision Screening in Children Aged 6 Months to 5 Years: US Preventive Services Task Force Recommendation Statement. JAMA. 2017 Sep 5;318(9):836-844. doi: 10.1001/jama.2017.11260. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivities for amblyopia risk factor detection | The sensitivity is the percentage of patients with amblyopia whose vision screen indicates they have an amblyopia risk factor. The sensitivity for the detection of amblyopia risk factors is determined individually for both the GoCheck Kids application and the Welch Allyn Spot Vision Screener by calculating the number of truly positive failed vision screens by the photoscreener (as determined by the gold standard physical exam including cycloplegic retinoscopy to look for refractive error and oculomotor exam to evaluate strabismus) and dividing by the sum of truly positive failed vision screens plus false-negative vision screens (the vision screener did not detect amblyopia risk factors when they were found to be present on the physical exam). | Up to 2 hours | |
Secondary | Sensitivity for detection of refractive error | The refractive error will be determined using the gold standard physical exam technique of cycloplegic retinoscopy. The sensitivity for the detection of refractive error will be determined individually for both the GoCheck Kids application and the Welch Allyn Spot Vision Screener by calculating the number of truly positive failed vision screens for refractive error and dividing by the sum of truly positive failed vision screens for refractive error plus false-negative vision screens for refractive error. | Up to 2 hours | |
Secondary | Sensitivity for detection of strabismus | The presence of strabismus will be determined using an oculomolotor exam. The sensitivity for the detection of strabismus will be determined individually for both the GoCheck Kids application and the Welch Allyn Spot Vision Screener by calculating the number of truly positive failed vision screens for strabismus and dividing by the sum of truly positive failed vision screens for strabismus plus false-negative vision screens for strabismus. | Up to 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04238065 -
A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia
|
N/A | |
Completed |
NCT04432181 -
Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
|
||
Terminated |
NCT02767856 -
Regimens of Intermittent Occlusion Therapy for Amblyopia in Children
|
N/A | |
Completed |
NCT02458846 -
Efficacy of Visual Screening in Ontario
|
N/A | |
Completed |
NCT01190813 -
Levodopa for the Treatment of Residual Amblyopia
|
Phase 3 | |
Completed |
NCT01109459 -
Multimodal Physician Intervention to Detect Amblyopia
|
N/A | |
Completed |
NCT04313257 -
Monocular Action Video Game Treatment of Amblyopia
|
N/A | |
Completed |
NCT04315649 -
Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops
|
N/A | |
Completed |
NCT05223153 -
OCT-A and Amblyopia
|
||
Recruiting |
NCT05522972 -
Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games
|
N/A | |
Completed |
NCT01430247 -
Vision Screening for the Detection of Amblyopia
|
N/A | |
Completed |
NCT02200211 -
Study of Binocular Computer Activities for Treatment of Amblyopia
|
N/A | |
Recruiting |
NCT06429280 -
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
|
||
Withdrawn |
NCT04959422 -
Assuring Ophthalmologic Follow up
|
N/A | |
Active, not recruiting |
NCT05612568 -
5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
|
||
Recruiting |
NCT03655912 -
Binocular Visual Therapy and Video Games for Amblyopia Treatment.
|
N/A | |
Recruiting |
NCT06150391 -
Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program
|
N/A | |
Completed |
NCT03754153 -
Binocularly Balanced Viewing Study
|
N/A | |
Terminated |
NCT02246556 -
Dichoptic Virtual Reality Therapy for Amblyopia in Adults
|
Phase 1 | |
Withdrawn |
NCT02594358 -
Caffeine in Amblyopia Study
|
Phase 1/Phase 2 |